Physician profile
Jonathan A Lesserson
NPI 1194764670
$3,172.03
in general payments reported to CMS, 2019-2025
20 companies · $939 in 2025
The $939 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $65.29 · 2021: $131 · 2022: $227 · 2023: $722 · 2024: $623 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,151.87 |
| Education | $133.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $698.73 | 2022-2025 | Nucala |
| Intersect Ent, INC. | $436.71 | 2019-2022 | |
| Genzyme Corporation | $407.71 | 2023-2025 | |
| Medtronic, INC. | $354.86 | 2023-2025 | Propel, Stealthstation S8 Platform |
| Stryker Corporation | $238.45 | 2019-2025 | Xpress Loprofile |
| Optinose US, INC. | $207.46 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $172.47 | 2023-2025 | Dupixent |
| Aerin Medical INC. | $148.87 | 2022-2025 | |
| Kaleo, INC. | $117.12 | 2022-2024 | Auvi-Q |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Qapel Medical INC | $94.90 | 2024 | |
| Amgen INC. | $34.00 | 2025 | |
| Paratek Pharmaceuticals, INC. | $33.68 | 2025 | Nuzyra, Xhance |
| Cochlear Americas | $28.63 | 2023 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Inspire Medical Systems, INC. | $25.72 | 2024 | Inspire |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $18.98 | 2019 | |
| Smith+Nephew, INC. | $16.22 | 2025 | Tula |
| Hikma Pharmaceuticals USA | $13.70 | 2025 | Ryaltris |
| Eyevance Pharmaceuticals LLC | $12.82 | 2020 | |
| Glenmark Therapeutics INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lesserson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.